Studies to Investigate the Mechanism of Action of Sunovion Compound SEP-856

Project: Research project

Description

Primary action of SEP856 in Smart Cube profile was antipsychotic, with antidepressant, mood stabilizing, and anxiolytic properties. This is comparable to the profile of an atypical antipsychotic drug (AAPD). Importantly, it does not block D2 or 5-HT2A receptors, which distinguishes it from all AAPDs, including pimavanserin. Pimavanserin is a selective 5-HT2A inverse agonist and produces an antipsychotic action in L-DOPA and Alzheimer’s psychosis and augments subeffective doses of risperidone in treating acute psychosis in schizophrenia patients.
StatusFinished
Effective start/end date4/26/184/26/19

Funding

  • Sunovion Pharmaceuticals Inc (Agmt 4/26/18)

Fingerprint

Antipsychotic Agents
Psychotic Disorders
Serotonin 5-HT2 Receptor Agonists
Receptor, Serotonin, 5-HT2A
Risperidone
Anti-Anxiety Agents
Antidepressive Agents
Schizophrenia
Pimavanserin